Photoluminescence properties of TiO2 nanofibers

Loubna Chetibi; Tetiana Busko; Nikolay Polikarpovich Kulish; Djamel Hamana; Sahraoui Chaieb; Slimane Achour

doi:10.1007/s11051-017-3822-x

Photoluminescence properties of TiO₂ nanofibers

Loubna Chetibi, Tetiana Busko, Nikolay Polikarpovich Kulish, Djamel Hamana, Sahraoui Chaieb, Slimane Achour^*

^*Corresponding author for this work

Biological, Environmental Sciences and Engineering

Research output: Contribution to journal › Article › peer-review

22 Scopus citations

Abstract

Multi-walled carbon nanotube (MWCNT)-TiO₂ nanofiber (NF) composites forming a layered nanostructure (MWCNTs/TiO₂ NFs/Ti) were prepared by impregnation at low temperature. Room temperature photoluminescence (PL) of these nanostructures shows a broad intense band in the visible light range (∼450–600 nm). The origin of the PL emission which, mainly, resulted from surface oxygen vacancies and other defects was investigated. We studied the effect of MWCNT deposition on the PL of TiO₂ NFs where the MWCNTs can act as an electron reservoir of electrons emitted from TiO₂ nanofibers when irradiated with UV light. The combination of MWCNTs and TiO₂ results in quenching of TiO₂ luminescence in the visible range. In addition, the prepared surface of MWCNTs-TiO₂ was irradiated with Ti⁺ ions using irradiation energy of 140 keV and doses of 10¹³ ions/cm². Also, this treatment induced the PL intensity quenching due to the generation of non-radiative additional levels inside the band gap. [Figure not available: see fulltext.]

Original language	English (US)
Article number	129
Journal	Journal of Nanoparticle Research
Volume	19
Issue number	4
DOIs	https://doi.org/10.1007/s11051-017-3822-x
State	Published - Apr 1 2017

Bibliographical note

Funding Information:
The American Heart Association Partnering with Regulators Learning Collaborative is part of the broader Value in Healthcare Initiative, a collaboration of the American Heart Association and the Robert J. Margolis, MD, Center for Health Policy at Duke University. The broader Value in Healthcare Initiative is supported in part by the American Heart Association and industry partners (Amgen, Bristol-Myers Squibb, the Bristol-Myers Squibb-Pfizer Alliance, and the Sanofi-Regeneron Alliance). American Heart Association volunteers (clinicians, patient representatives, and other experts) received reimbursement for travel to project meetings, but no other compensation was provided to Learning Collaborative members. The views of this article do not necessarily represent the views of the Learning Collaborative members or the organizations that they represent. Learning Collaborative members provided feedback on the content of this article, but the content of the article was independently determined by the Duke-Margolis Center, which is part of Duke University, and as such honors the tradition of academic independence on the part of its faculty and scholars. Neither Duke nor the Margolis Center takes partisan positions, but the individual members are free to speak their minds and express their opinions

Funding Information:
Dr Bleser has previously received consulting fees from Merck on vaccine litigation unrelated to this work and serves as Board Vice President (uncompensated) for Shepherd’s Clinic, a clinic providing free healthcare to the uninsured in Baltimore, MD. Dr Saunders has a Consulting Agreement with Yale–New Haven Health System for development of measures and development of quality measurement strategies for Center for Medicare & Medicaid Innovation Alternative Payment Models under Centers for Medicare & Medicaid Services Contract Number 75FCMC18D0042/Task Order Number 75FCMC19F0003, Quality Measure Development, and Analytic Support, Base Period. Dr Wang reports receiving research grants to the Duke Clinical Research Institute from Astra-Zeneca, Bristol-Myers Squibb, Cryolife, Chiesi, Merck, Portola, and Regeneron and receiving honoraria from AstraZeneca, Cryolife, and Sanofi. Dr Hernan-dez reports receiving research funding from American Regent, AstraZeneca, Merck, Novartis, and Verily and receiving consulting fees from Amgen, Astra-Zeneca, Bayer, Boston Scientific, Merck, Novartis, and Relypsa. Dr McClellan is an independent board member on the boards of Johnson & Johnson, Cigna, Alignment Healthcare, and Seer; co-chairs the Accountable Care Learning Collaborative and the Guiding Committee for the Health Care Payment Learning and Action Network; and receives fees for serving as an advisor for Cota and MITRE. Dr Califf is an employee of Verily Life Sciences and Google Life Sciences and is a board member of Cytokinetics. The other authors report no conflicts.

Publisher Copyright:
© 2017, Springer Science+Business Media Dordrecht.

Keywords

Irradiation
MWCNTs
Photoluminescence
Recombination
TiO nanofibers

ASJC Scopus subject areas

Bioengineering
Atomic and Molecular Physics, and Optics
Chemistry(all)
Modeling and Simulation
Materials Science(all)
Condensed Matter Physics

Access to Document

10.1007/s11051-017-3822-x

Cite this

@article{4552bf2ee97e45ceb4af3a4962d601d8,

title = "Photoluminescence properties of TiO2 nanofibers",

abstract = "Multi-walled carbon nanotube (MWCNT)-TiO2 nanofiber (NF) composites forming a layered nanostructure (MWCNTs/TiO2 NFs/Ti) were prepared by impregnation at low temperature. Room temperature photoluminescence (PL) of these nanostructures shows a broad intense band in the visible light range (∼450–600 nm). The origin of the PL emission which, mainly, resulted from surface oxygen vacancies and other defects was investigated. We studied the effect of MWCNT deposition on the PL of TiO2 NFs where the MWCNTs can act as an electron reservoir of electrons emitted from TiO2 nanofibers when irradiated with UV light. The combination of MWCNTs and TiO2 results in quenching of TiO2 luminescence in the visible range. In addition, the prepared surface of MWCNTs-TiO2 was irradiated with Ti+ ions using irradiation energy of 140 keV and doses of 1013 ions/cm2. Also, this treatment induced the PL intensity quenching due to the generation of non-radiative additional levels inside the band gap. [Figure not available: see fulltext.]",

keywords = "Irradiation, MWCNTs, Photoluminescence, Recombination, TiO nanofibers",

author = "Loubna Chetibi and Tetiana Busko and Kulish, {Nikolay Polikarpovich} and Djamel Hamana and Sahraoui Chaieb and Slimane Achour",

note = "Funding Information: The American Heart Association Partnering with Regulators Learning Collaborative is part of the broader Value in Healthcare Initiative, a collaboration of the American Heart Association and the Robert J. Margolis, MD, Center for Health Policy at Duke University. The broader Value in Healthcare Initiative is supported in part by the American Heart Association and industry partners (Amgen, Bristol-Myers Squibb, the Bristol-Myers Squibb-Pfizer Alliance, and the Sanofi-Regeneron Alliance). American Heart Association volunteers (clinicians, patient representatives, and other experts) received reimbursement for travel to project meetings, but no other compensation was provided to Learning Collaborative members. The views of this article do not necessarily represent the views of the Learning Collaborative members or the organizations that they represent. Learning Collaborative members provided feedback on the content of this article, but the content of the article was independently determined by the Duke-Margolis Center, which is part of Duke University, and as such honors the tradition of academic independence on the part of its faculty and scholars. Neither Duke nor the Margolis Center takes partisan positions, but the individual members are free to speak their minds and express their opinions Funding Information: Dr Bleser has previously received consulting fees from Merck on vaccine litigation unrelated to this work and serves as Board Vice President (uncompensated) for Shepherd{\textquoteright}s Clinic, a clinic providing free healthcare to the uninsured in Baltimore, MD. Dr Saunders has a Consulting Agreement with Yale–New Haven Health System for development of measures and development of quality measurement strategies for Center for Medicare & Medicaid Innovation Alternative Payment Models under Centers for Medicare & Medicaid Services Contract Number 75FCMC18D0042/Task Order Number 75FCMC19F0003, Quality Measure Development, and Analytic Support, Base Period. Dr Wang reports receiving research grants to the Duke Clinical Research Institute from Astra-Zeneca, Bristol-Myers Squibb, Cryolife, Chiesi, Merck, Portola, and Regeneron and receiving honoraria from AstraZeneca, Cryolife, and Sanofi. Dr Hernan-dez reports receiving research funding from American Regent, AstraZeneca, Merck, Novartis, and Verily and receiving consulting fees from Amgen, Astra-Zeneca, Bayer, Boston Scientific, Merck, Novartis, and Relypsa. Dr McClellan is an independent board member on the boards of Johnson & Johnson, Cigna, Alignment Healthcare, and Seer; co-chairs the Accountable Care Learning Collaborative and the Guiding Committee for the Health Care Payment Learning and Action Network; and receives fees for serving as an advisor for Cota and MITRE. Dr Califf is an employee of Verily Life Sciences and Google Life Sciences and is a board member of Cytokinetics. The other authors report no conflicts. Publisher Copyright: {\textcopyright} 2017, Springer Science+Business Media Dordrecht.",

year = "2017",

month = apr,

day = "1",

doi = "10.1007/s11051-017-3822-x",

language = "English (US)",

volume = "19",

journal = "Journal of Nanoparticle Research",

issn = "1388-0764",

publisher = "Springer Verlag",

number = "4",

}

TY - JOUR

T1 - Photoluminescence properties of TiO2 nanofibers

AU - Chetibi, Loubna

AU - Busko, Tetiana

AU - Kulish, Nikolay Polikarpovich

AU - Hamana, Djamel

AU - Chaieb, Sahraoui

AU - Achour, Slimane

N1 - Funding Information: The American Heart Association Partnering with Regulators Learning Collaborative is part of the broader Value in Healthcare Initiative, a collaboration of the American Heart Association and the Robert J. Margolis, MD, Center for Health Policy at Duke University. The broader Value in Healthcare Initiative is supported in part by the American Heart Association and industry partners (Amgen, Bristol-Myers Squibb, the Bristol-Myers Squibb-Pfizer Alliance, and the Sanofi-Regeneron Alliance). American Heart Association volunteers (clinicians, patient representatives, and other experts) received reimbursement for travel to project meetings, but no other compensation was provided to Learning Collaborative members. The views of this article do not necessarily represent the views of the Learning Collaborative members or the organizations that they represent. Learning Collaborative members provided feedback on the content of this article, but the content of the article was independently determined by the Duke-Margolis Center, which is part of Duke University, and as such honors the tradition of academic independence on the part of its faculty and scholars. Neither Duke nor the Margolis Center takes partisan positions, but the individual members are free to speak their minds and express their opinions Funding Information: Dr Bleser has previously received consulting fees from Merck on vaccine litigation unrelated to this work and serves as Board Vice President (uncompensated) for Shepherd’s Clinic, a clinic providing free healthcare to the uninsured in Baltimore, MD. Dr Saunders has a Consulting Agreement with Yale–New Haven Health System for development of measures and development of quality measurement strategies for Center for Medicare & Medicaid Innovation Alternative Payment Models under Centers for Medicare & Medicaid Services Contract Number 75FCMC18D0042/Task Order Number 75FCMC19F0003, Quality Measure Development, and Analytic Support, Base Period. Dr Wang reports receiving research grants to the Duke Clinical Research Institute from Astra-Zeneca, Bristol-Myers Squibb, Cryolife, Chiesi, Merck, Portola, and Regeneron and receiving honoraria from AstraZeneca, Cryolife, and Sanofi. Dr Hernan-dez reports receiving research funding from American Regent, AstraZeneca, Merck, Novartis, and Verily and receiving consulting fees from Amgen, Astra-Zeneca, Bayer, Boston Scientific, Merck, Novartis, and Relypsa. Dr McClellan is an independent board member on the boards of Johnson & Johnson, Cigna, Alignment Healthcare, and Seer; co-chairs the Accountable Care Learning Collaborative and the Guiding Committee for the Health Care Payment Learning and Action Network; and receives fees for serving as an advisor for Cota and MITRE. Dr Califf is an employee of Verily Life Sciences and Google Life Sciences and is a board member of Cytokinetics. The other authors report no conflicts. Publisher Copyright: © 2017, Springer Science+Business Media Dordrecht.

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Multi-walled carbon nanotube (MWCNT)-TiO2 nanofiber (NF) composites forming a layered nanostructure (MWCNTs/TiO2 NFs/Ti) were prepared by impregnation at low temperature. Room temperature photoluminescence (PL) of these nanostructures shows a broad intense band in the visible light range (∼450–600 nm). The origin of the PL emission which, mainly, resulted from surface oxygen vacancies and other defects was investigated. We studied the effect of MWCNT deposition on the PL of TiO2 NFs where the MWCNTs can act as an electron reservoir of electrons emitted from TiO2 nanofibers when irradiated with UV light. The combination of MWCNTs and TiO2 results in quenching of TiO2 luminescence in the visible range. In addition, the prepared surface of MWCNTs-TiO2 was irradiated with Ti+ ions using irradiation energy of 140 keV and doses of 1013 ions/cm2. Also, this treatment induced the PL intensity quenching due to the generation of non-radiative additional levels inside the band gap. [Figure not available: see fulltext.]

AB - Multi-walled carbon nanotube (MWCNT)-TiO2 nanofiber (NF) composites forming a layered nanostructure (MWCNTs/TiO2 NFs/Ti) were prepared by impregnation at low temperature. Room temperature photoluminescence (PL) of these nanostructures shows a broad intense band in the visible light range (∼450–600 nm). The origin of the PL emission which, mainly, resulted from surface oxygen vacancies and other defects was investigated. We studied the effect of MWCNT deposition on the PL of TiO2 NFs where the MWCNTs can act as an electron reservoir of electrons emitted from TiO2 nanofibers when irradiated with UV light. The combination of MWCNTs and TiO2 results in quenching of TiO2 luminescence in the visible range. In addition, the prepared surface of MWCNTs-TiO2 was irradiated with Ti+ ions using irradiation energy of 140 keV and doses of 1013 ions/cm2. Also, this treatment induced the PL intensity quenching due to the generation of non-radiative additional levels inside the band gap. [Figure not available: see fulltext.]

KW - Irradiation

KW - MWCNTs

KW - Photoluminescence

KW - Recombination

KW - TiO nanofibers

UR - http://www.scopus.com/inward/record.url?scp=85016560068&partnerID=8YFLogxK

U2 - 10.1007/s11051-017-3822-x

DO - 10.1007/s11051-017-3822-x

M3 - Article

AN - SCOPUS:85016560068

SN - 1388-0764

VL - 19

JO - Journal of Nanoparticle Research

JF - Journal of Nanoparticle Research

IS - 4

M1 - 129

ER -